Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 3/20 | 0.49 |
| ▸ | ALPG | P10696 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PLAA | Q9Y263 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9768072 | 0.98 | ALPG (0.48) | ALDH1A1HPGDALPLALPGMEN1 | |
| SCHEMBL6890171 | 0.78 | MEN1 (0.62) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL19144755 | 0.76 | MEN1 (0.45) | ALDH1A1HPGDMEN1KMT2ACXCR4 | |
| SCHEMBL8930279 | 0.76 | MEN1 (0.60) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL9768145 | 0.75 | ALPG (0.46) | ALPLALPGERCC1ERCC4HDAC1 | |
| SCHEMBL5325765 | 0.73 | ALDH1A1 (0.49) | ALDH1A1HPGDMEN1KMT2ACXCR4 | |
| Adrenalone SCHEMBL29550997 | 0.72 | ALPG (0.55) | ALPLALPGMEN1KMT2AHDAC6 | |
| SCHEMBL14646958 | 0.72 | ALPG (0.51) | ALPLALPGHDAC6PLAAKDM4E | |
| Adrenalone SCHEMBL123124 | 0.72 | ALPG (0.55) | ALPLALPGMEN1KMT2AHDAC6 | |
| SCHEMBL9768178 | 0.71 | KDM4E (0.53) | ALDH1A1HPGDALPLALPGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266817-B2 | Catecholamine derivatives for obesity and neurological disorders | EMORY UNIVERSITY (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010107866-A2 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | ALDH1A1 412/4885HPGD 1609/4885ALPL 4539/4885 |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | ALDH1A1 412/4885HPGD 1609/4885ALPL 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.